FDA Gives Nod to Generic Lexapro Tablets
Drug treats depressive and anxiety disorders (Sept. 13)
Lupin Ltd., headquartered in Mumbai, India, announced on September 13 that its Baltimore-based subsidiary, Lupin Pharmaceuticals Inc., has received final approval from the FDA to market its escitalopram tablets (escitalopram oxalate) 5 mg, 10 mg, and 20 mg — a generic equivalent of Forest Laboratories, Inc.’s Lexapro tablets 5 mg, 10 mg, and 20 mg.
Escitalopram is indicated for acute and maintenance treatment of major depressive disorder in adolescents aged 12 to 17 years and in adults. It is also indicated for the acute treatment of generalized anxiety disorder in adults.
Lexapro tablets had U.S. sales of approximately $2.7 billion for the 12 months ending June 2012.
For more information, visit the Lupin Ltd. Web site.